Zaffaroni N - Search Results

1

Design of Disruptors of the Hsp90-Cdc37 Interface.

D'Annessa I, Hurwitz N, Pirota V, Beretta GL, Tinelli S, Woodford M, Freccero M, Mollapour M, Zaffaroni N, Wolfson H, Colombo G. D'Annessa I, et al. Among authors: zaffaroni n. Molecules. 2020 Jan 15;25(2):360. doi: 10.3390/molecules25020360. Molecules. 2020. PMID: 31952296 Free PMC article.

2

Role of proliferation in HER2 status predicted response to doxorubicin.

Campiglio M, Somenzi G, Olgiati C, Beretta G, Balsari A, Zaffaroni N, Valagussa P, Ménard S. Campiglio M, et al. Among authors: zaffaroni n. Int J Cancer. 2003 Jul 1;105(4):568-73. doi: 10.1002/ijc.11113. Int J Cancer. 2003. PMID: 12712452 Free article. Clinical Trial.

3

Rational design of shepherdin, a novel anticancer agent.

Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, Meli M, Dohi T, Fortugno P, Nefedova Y, Gabrilovich DI, Colombo G, Altieri DC. Plescia J, et al. Among authors: zaffaroni n. Cancer Cell. 2005 May;7(5):457-68. doi: 10.1016/j.ccr.2005.03.035. Cancer Cell. 2005. PMID: 15894266 Free article.

4

Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.

Meli M, Pennati M, Curto M, Daidone MG, Plescia J, Toba S, Altieri DC, Zaffaroni N, Colombo G. Meli M, et al. Among authors: zaffaroni n. J Med Chem. 2006 Dec 28;49(26):7721-30. doi: 10.1021/jm060836y. J Med Chem. 2006. PMID: 17181154

5

Synthesis and topoisomerase I inhibitory activity of a novel diazaindeno[2,1-b]phenanthrene analogue of Lamellarin D.

Cananzi S, Merlini L, Artali R, Beretta GL, Zaffaroni N, Dallavalle S. Cananzi S, et al. Among authors: zaffaroni n. Bioorg Med Chem. 2011 Aug 15;19(16):4971-84. doi: 10.1016/j.bmc.2011.06.056. Epub 2011 Jul 2. Bioorg Med Chem. 2011. PMID: 21783369

6

Novel insights into targeting ATP-binding cassette transporters for antitumor therapy.

Gatti L, Cossa G, Beretta GL, Zaffaroni N, Perego P. Gatti L, et al. Among authors: zaffaroni n. Curr Med Chem. 2011;18(27):4237-49. doi: 10.2174/092986711797189682. Curr Med Chem. 2011. PMID: 21838682 Review.

7

Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition.

Perego P, Cossa G, Tinelli S, Corna E, Carenini N, Gatti L, De Cesare M, Ciusani E, Zunino F, Luison E, Canevari S, Zaffaroni N, Beretta GL. Perego P, et al. Among authors: zaffaroni n. Biochem Pharmacol. 2012 Jan 1;83(1):27-36. doi: 10.1016/j.bcp.2011.09.021. Epub 2011 Sep 29. Biochem Pharmacol. 2012. PMID: 21978643

8

Targeting DNA topoisomerase I with non-camptothecin poisons.

Beretta GL, Zuco V, Perego P, Zaffaroni N. Beretta GL, et al. Among authors: zaffaroni n. Curr Med Chem. 2012;19(8):1238-57. doi: 10.2174/092986712799320529. Curr Med Chem. 2012. PMID: 22204335 Review.

9

Hybrid ligand-alkylating agents targeting telomeric G-quadruplex structures.

Doria F, Nadai M, Folini M, Di Antonio M, Germani L, Percivalle C, Sissi C, Zaffaroni N, Alcaro S, Artese A, Richter SN, Freccero M. Doria F, et al. Among authors: zaffaroni n. Org Biomol Chem. 2012 Apr 14;10(14):2798-806. doi: 10.1039/c2ob06816h. Epub 2012 Feb 27. Org Biomol Chem. 2012. PMID: 22367401

10

Namitecan: a hydrophilic camptothecin with a promising preclinical profile.

Beretta GL, Zuco V, De Cesare M, Perego P, Zaffaroni N. Beretta GL, et al. Among authors: zaffaroni n. Curr Med Chem. 2012;19(21):3488-501. doi: 10.2174/092986712801323252. Curr Med Chem. 2012. PMID: 22680917 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

333 results

Search Page